Vicki Sato Biography and Net Worth

Vicki Sato, Ph.D., has served as Chairman of our board of directors since December 2016. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc., or Vertex, a publicly-traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen Inc. Dr. Sato is a member of the board of directors of the following public companies: Akouos, Allogene Therapeutics, and Denali Therapeutics, Inc. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.

What is Vicki L. Sato's net worth?: The estimated net worth of Vicki L. Sato is at least $1.17 million as of April 15th, 2024. Dr. Sato owns 118,043 shares of Vir Biotechnology stock worth more than $1,172,167 as of May 7th. This net worth approximation does not reflect any other assets that Dr. Sato may own. Learn More about Vicki L. Sato's net worth.
How do I contact Vicki L. Sato?: The corporate mailing address for Dr. Sato and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Vicki L. Sato's contact information.
Has Vicki L. Sato been buying or selling shares of Vir Biotechnology?: Vicki L. Sato has not been actively trading shares of Vir Biotechnology over the course of the past ninety days. Most recently, Vicki L. Sato sold 18,000 shares of the business's stock in a transaction on Friday, June 30th. The shares were sold at an average price of $24.66, for a transaction totalling $443,880.00. Following the completion of the sale, the director now directly owns 1,315,351 shares of the company's stock, valued at $32,436,555.66. Learn More on Vicki L. Sato's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 23 times. They sold a total of 688,972 shares worth more than $15,517,627.33. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/3/2024.

Vicki L. Sato Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2023	Sell	18,000	$24.66	$443,880.00	1,315,351
3/8/2023	Sell	17,935	$22.59	$405,151.65	1,327,324
2/8/2023	Sell	17,915	$28.38	$508,427.70	1,345,259
1/9/2023	Sell	17,915	$25.83	$462,744.45	1,363,174
11/8/2022	Sell	17,915	$27.38	$490,512.70	1,399,004
10/10/2022	Sell	17,915	$20.67	$370,303.05	1,416,919
9/8/2022	Sell	17,915	$21.90	$392,338.50	1,434,834
7/8/2022	Sell	17,915	$29.06	$520,609.90	1,470,664
6/8/2022	Sell	17,915	$25.84	$462,923.60	1,488,579
5/9/2022	Sell	14,541	$20.62	$299,835.42	1,503,463
4/28/2022	Sell	17,915	$20.90	$374,423.50	1,518,004
1/18/2022	Sell	15,173	$37.39	$567,318.47
12/20/2021	Sell	15,174	$54.53	$827,438.22
11/26/2021	Sell	15,174	$36.80	$558,403.20
10/19/2021	Sell	15,174	$39.56	$600,283.44
9/17/2021	Sell	15,174	$52.48	$796,331.52
8/19/2021	Sell	15,174	$45.05	$683,588.70	1,620,833
7/19/2021	Sell	15,174	$37.20	$564,472.80	1,633,325
6/21/2021	Sell	15,174	$46.17	$700,583.58	1,645,429
5/19/2021	Sell	15,174	$43.80	$664,621.20	1,660,782

Vicki L. Sato Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $9.93

$9.86

$10.46

50 Day Range

MA: $9.76

$7.63

$11.60

2 Week Range

Now: $9.93

$7.61

$27.48

Volume

807,406 shs

Average Volume

1,049,567 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report